CLINICAL TRIALS AND OBSERVATIONS Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
نویسندگان
چکیده
Paola Guglielmelli,1 Giovanni Barosi,2 Alessandro Rambaldi,3 Roberto Marchioli,4 Arianna Masciulli,4 Lorenzo Tozzi,1 Flavia Biamonte,1 Niccolò Bartalucci,1 Elisabetta Gattoni,2 Maria Letizia Lupo,2 Guido Finazzi,3 Alessandro Pancrazzi,1 Elisabetta Antonioli,1 Maria Chiara Susini,1 Lisa Pieri,1 Elisa Malevolti,1 Emilio Usala,5 Ubaldo Occhini,6 Alberto Grossi,7 Silvia Caglio,8 Simona Paratore,8 Alberto Bosi,1 Tiziano Barbui,3 and Alessandro M. Vannucchi,1 on behalf of the AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators
منابع مشابه
Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches.
The treatment landscape and biologic understanding of neuroendocrine tumors (NET) has shifted dramatically in recent years. Recent studies have shown that somatostatin analogues have the potential not only to control symptoms of hormone hypersecretion but also have the ability to slow tumor growth in patients with advanced carcinoid. The results of clinical trials have further shown that the VE...
متن کاملSystemic treatment for hereditary cancers: a 2012 update
The history of specific therapy for hereditary tumors dates back to mid 1980s and involves a number of reports demonstrating regression of familial colon polyps upon administration of sulindac. Virtually no clinical studies on other hereditary cancer types were available until the year 2009, when Byrski et al. presented the data on unprecedented sensitivity of BRCA1-associated breast malignanci...
متن کاملSystemic therapy for hereditary cancer
The history of specific therapy for hereditary tumors dates back to mid 1980s and involves a number of reports demonstrating regression of familial colon polyps upon administration of sulindac. Virtually no clinical studies on other hereditary cancer types were available until the year 2009, when Byrski et al. presented the data on unprecedented sensitivity of BRCA1-associated breast malignanci...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
Ruxolitinib is JAK1/JAK2 inhibitor with established clinical benefit in myelofibrosis (MF). We analyzed long-term outcomes of 107 patients with intermediate-2 or high-risk MF receiving ruxolitinib at MD Anderson Cancer Center (MDACC) on phase 1/2 trial. After a median of 32 months of follow-up, 58 patients (54%) were still receiving ruxolitinib, with overall survival (OS) of 69%. The splenomega...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)
Tumor necrosis factor (TNF) and vascular endothelial growth factor (VEGF) play an important role in the biology of chronic lymphocytic leukemia (CLL) cells. Thalidomide is a first-generation immunomodulating agent that down-regulates TNFand VEGF. We initiated a phase 1/2 clinical trial to determine the safety and efficacy of combining thalidomide with fludarabine in patients with treatmentnaı̈ve...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2011